Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001178913-25-001065
Filing Date
2025-03-27
Accepted
2025-03-27 08:30:11
Documents
6
Period of Report
2025-03-27

Document Format Files

Seq Description Document Type Size
1 6-K zk2532931.htm 6-K 11007
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 26308
3 image00001.jpg GRAPHIC 70904
4 image1.jpg GRAPHIC 68417
5 image00003.jpg GRAPHIC 193724
6 image3.jpg GRAPHIC 242583
  Complete submission text file 0001178913-25-001065.txt   831588
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38807 | Film No.: 25775451
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)